Lung Cancer     

FOI REFERENCE: 24437  FOI DATE: 15^th October 2024    

Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

• ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)  4 Patients
• Amivantamab 0 Patients
• Atezolizumab Monotherapy 14 Patients
• Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel 1 Patient
• Atezolizumab subcutaneous 0 Patients
• Dabrafenib + Trametinib 0 Patients
• Docetaxel monotherapy or in combination with Carboplatin/Cisplatin 0 Patients
• Durvalumab 0 Patients
• Gemcitabine 0 Patients
• Nintedanib + Docetaxel 0 Patients
• Nivolumab  5 Patients
• Osimertinib   23 Patients
• Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)  0 Patients
• Paclitaxel 1 Patient
• Pembrolizumab Monotherapy 28 Patients
• Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) 3 Patients
• Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) 5 Patients
• Pemetrexed + Platinum (Carboplatin/Cisplatin) 13 Patients
• RET Inhibitors (Pralsetinib, Selpercatinib) 1 Patient
• Sotorasib 3 Patients
• Tepotinib 3 Patients
• Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin 19 Patients
• Other active systemic anti-cancer therapy
• Palliative care only 135 Patients

Q2. How many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY in the past 3 months with:

• Atezolizumab monotherapy 4 Patients
• Durvalumab 0 Patients
• Gemcitabine 0 Patients
• Nivolumab 4 Patients
• Osimertinib 1 Patient
• Pembrolizumab Monotherapy 10 Patients
• Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) 3 Patients
• Paclitaxel 1 Patient
• Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin 12 Patients
• Other active systemic anti-cancer therapy (SACT)
• Palliative care only 31 Patients